Expanding the clinical spectrum of autoimmune inflammatory myopathies with prominent B cell aggregates: a case series

This retrospective case series of 22 patients with autoimmune inflammatory myopathies featuring prominent B cell aggregates reveals a distinct clinical phenotype characterized by frequent comorbid systemic autoimmune diseases and specific muscle weakness patterns, alongside novel pathophysiological insights showing the presence of tertiary lymphoid structures in muscle biopsies.

The Gist

The Big Picture: A Mystery in the Muscle

Imagine your muscles are like a busy city. Usually, this city runs smoothly. But in a group of diseases called Autoimmune Inflammatory Myopathies (AIM), the city's security force (the immune system) gets confused and starts attacking the muscle buildings instead of protecting them.

For a long time, doctors knew that T-cells (a type of security guard) were the main troublemakers in these cities. But recently, researchers noticed something strange in some patients: huge, organized B-cell aggregates.

Think of B-cells as the "special forces" or the "intelligence officers" of the immune system. Usually, they hang out in lymph nodes (like police headquarters). Finding them in the muscle tissue is rare. Even rarer is finding them organized into big, structured clusters.

This study looked at a group of patients who had these strange B-cell clusters in their muscles and tried to figure out: Who are these patients? What do they look like? And what are these clusters actually doing?

---

1. Who are these patients? (The "Double Trouble" Group)

The researchers found that patients with these B-cell clusters are a unique bunch.

• The "Double Trouble" Connection: Most of these patients (82%) didn't just have muscle problems; they also had another autoimmune disease. It's like having two different fires burning at once. The most common "second fire" was Systemic Sclerosis (scleroderma) or Rheumatoid Arthritis.
• The Weakness Pattern: Old textbooks said these patients usually had weakness in their neck and upper arms (like a "brachio-cervical" pattern). However, this study found that the reality is messier. While some fit that description, many had weakness all over, or just in their legs. It turns out you can't guess who has these B-cell clusters just by looking at how they walk; you need to look under the microscope.

2. The "Squatters" in the Muscle (Tertiary Lymphoid Structures)

This is the most exciting part of the paper. The researchers used a high-tech "super-microscope" (called Cyclic Immunofluorescence) to take a 3D, multi-layered look at the muscle tissue.

They discovered that these B-cell clusters aren't just random piles of cells. They are Tertiary Lymphoid Structures (TLS).

The Analogy:
Imagine a neighborhood (the muscle) that is under attack.

• Normal situation: The police (immune cells) patrol the streets and go back to the station (lymph nodes) to get orders.
• The TLS situation: The neighborhood is so chaotic that the police decide to build their own mini-station right there in the middle of the neighborhood.

These "mini-stations" (TLS) are fully functional. They have:

• Command Centers: Where B-cells learn to make specific weapons (antibodies) to fight the muscle.
• Training Camps: Where cells get taught how to attack.
• Supply Lines: A constant flow of new recruits (naive cells) and experienced veterans (memory cells).

The study found that these muscle "mini-stations" contain all the necessary ingredients to keep the immune system angry and active, essentially turning the muscle into a permanent war zone.

3. The "Extra" Pathways (The Wild Cards)

Inside these muscle mini-stations, the researchers saw two types of activity:

1. The "Germinal Center" (The School): A structured place where B-cells learn to make perfect, high-quality weapons.
2. The "Extrafollicular" Pathway (The Street Fighters): A faster, messier route where B-cells quickly turn into "plasmablasts" (short-lived weapon factories) without all the training.

The study found that both pathways were active. It's like the muscle has both a formal military academy and a street gang, and both are producing weapons that hurt the patient. This explains why the disease can be so stubborn.

4. What does this mean for treatment?

• The Good News: Many of these patients responded well to standard treatments (like methotrexate or steroids). They aren't all hopeless cases.
• The Target: Since these "mini-stations" are built by B-cells, the logical fix is to use Rituximab, a drug that specifically wipes out B-cells.
  • In the study, about a third of patients got this drug. About half of them got better.
  • However, two patients who looked like they had a different disease (Inclusion Body Myositis) didn't respond well to anything. This suggests that if the "mini-station" is too advanced or mixed with other problems, B-cell drugs might not work alone.

The Takeaway

This study is like a detective story that solved a mystery about a specific type of muscle disease.

1. The Clue: Finding big B-cell clusters in muscle biopsies.
2. The Discovery: These aren't just random messes; they are organized "mini-immune-systems" (Tertiary Lymphoid Structures) built right inside the muscle.
3. The Implication: Because these structures are so complex, they might be the reason the disease keeps coming back. Understanding them gives doctors a new map to find better treatments, specifically targeting the "mini-stations" to stop the war before it starts.

In short: The immune system didn't just invade the muscle; it built a fortress inside it. To win the battle, we need to learn how to dismantle that fortress.

Technical Summary

1. Problem Statement

Autoimmune inflammatory myopathies (AIM) are heterogeneous diseases characterized by muscle inflammation. While T-cell infiltration is well-documented, the role of B cells remains poorly understood. Prominent B cell aggregates (BCM) on muscle biopsy are a rare finding, historically associated with a specific "brachio-cervical" weakness pattern and overlapping autoimmune diseases (e.g., Rheumatoid Arthritis, Systemic Sclerosis). However, existing literature consists primarily of small case series with limited clinical characterization. Furthermore, the pathophysiological significance of these aggregates is unclear: do they represent non-specific inflammation or organized Tertiary Lymphoid Structures (TLS) capable of driving local autoimmunity (similar to those seen in Lupus Nephritis or Rheumatoid Arthritis)? There is a lack of large-scale data comparing BCM patients to other AIM subtypes and a need for high-resolution spatial analysis to define the cellular architecture of these aggregates.

2. Methodology

The study employed a retrospective case-control design using the Canadian Inflammatory Myopathy Study (CIMS) cohort.

• Cohort: 69 patients were included:
  • Cases (BCM, n=22): Defined by muscle biopsy showing $\ge$30 CD20+ B cells per aggregate.
  • Controls (n=47): Included Dermatomyositis (DM, n=24), Overlap Myositis (OM, n=14), and Inclusion Body Myositis (IBM, n=9).
• Clinical Data: Comprehensive phenotyping included demographics, muscle strength (MMT8), extra-muscular features (ILD, arthritis, Raynaud's), serology (autoantibodies), and treatment response.
• Histopathology: Standard staining (H&E, immunohistochemistry for CD20, CD4, CD8, etc.) was performed. Aggregates were classified as "B cell rich" (30–99 cells) or "follicle-like" ($\ge$100 cells).
• Advanced Spatial Analysis (Key Innovation):
  • Cyclic Immunofluorescence (Cyc-IF): Performed on 45 biopsies (17 BCM, 28 controls) using a 22-marker panel.
  • Workflow: Tissue sections underwent 7 rounds of staining, imaging, and signal quenching.
  • Image Processing: Automated segmentation and feature extraction using ASHLAR (for registration) and QiTissue.
  • Spatial Metrics: Euclidean distance analysis was used to map cell-to-cell interactions within specific zones:
    • Cell-to-cell interaction zone: 0–75 $\mu$m.
    • Paracrine interaction zone: 0–200 $\mu$m.
  • Validation: Clustering stability was verified using the Adjusted Rand Index (ARI) to confirm the 30-cell (aggregate) and 100-cell (follicle) thresholds.

3. Key Contributions

• Largest Cohort to Date: This is the largest series of AIM patients with prominent B cell aggregates reported, allowing for robust statistical comparison against standard AIM subtypes.
• Clinical Spectrum Redefinition: The study challenges the historical view that BCM is strictly a "brachio-cervical" phenotype, demonstrating a much broader and heterogeneous clinical presentation.
• TLS Confirmation: The study provides the first high-resolution spatial evidence that B cell aggregates in AIM muscle tissue function as Tertiary Lymphoid Structures (TLS), containing the necessary cellular components for germinal center reactions and extrafollicular pathways.
• Methodological Advancement: Demonstrates the utility of Cyc-IF in detecting TLS that are missed by conventional CD20 staining, suggesting under-diagnosis of this phenotype in routine pathology.

4. Key Results

Clinical Characteristics

• Demographics: Mean age 51 years; 77% female.
• Autoimmune Overlap: 82% of BCM patients had an associated autoimmune disease, predominantly Systemic Sclerosis (55%) and Rheumatoid Arthritis (23%).
• Muscle Weakness Pattern: Contrary to previous reports of dominant brachio-cervical weakness, only 33% of BCM patients had upper extremity predominant weakness.
  • Neck Flexors: Frequently weak (77%).
  • Neck Extensors: Rarely weak (7%), contrasting with the classic description.
  • Distribution: Weakness was often generalized; upper extremities were weaker than lower extremities in 33% of cases.
• Treatment Response: 62% responded to first-line immunosuppression (e.g., Methotrexate). While 32% received Rituximab (B-cell depleting), only 57% of those showed clinical improvement. Notably, patients with an IBM phenotype within the BCM group were refractory to treatment.

Serology

• Autoantibodies: 78% of BCM patients were positive for myositis-specific or associated antibodies.
  • Most common: Anti-PM-Scl (27%), Anti-Ku (14%), and Anti-RF/CCP (9%).
  • ANA positivity was high (86%), with speckled and nucleolar patterns being most common.

Spatial Analysis (Cyc-IF) Findings

• TLS Identification: 7 cases showed TLS on Cyc-IF that were not visible on standard CD20 staining.
• Cellular Composition: BCM aggregates contained significantly higher densities of B cells, T cells, dendritic cells, and macrophages compared to non-BCM muscle tissue.
• Germinal Center Features: Enrichment of centroblasts, switched memory B cells, and T follicular helper (Tfh) markers indicated active germinal center reactions.
• Extrafollicular Pathway: Significant enrichment of Double Negative (DN) B cells (DN1, DN2, DN3, DN4) and T peripheral helper (Tph) cells suggested an active extrafollicular pathway, a mechanism known to drive pathogenic autoantibody production in SLE.
• Interferon Signature: Enrichment of MxA+ macrophages within aggregates indicated a Type I Interferon signature, linking TLS formation to the known interferonopathy of AIM.
• Spatial Organization:
  • 0–75 $\mu$m: Enriched with DN B cells, centroblasts, and antigen-presenting cells (DCs, CD169+ macrophages), suggesting active antigen presentation and B-cell proliferation.
  • 0–200 $\mu$m: Enriched with Tph cells, plasmablasts, and plasma cells, suggesting a paracrine environment supporting differentiation and antibody secretion.

5. Significance and Conclusion

This study fundamentally expands the understanding of B cell-mediated myositis:

1. Clinical Heterogeneity: BCM is not a monolithic "brachio-cervical" disease but a spectrum that can mimic DM, OM, or IBM. Clinical features alone cannot distinguish BCM from other AIM subtypes; histology is required.
2. Pathophysiology: The muscle tissue in BCM patients acts as an ectopic lymphoid organ. The presence of TLS implies that the muscle is a site of local autoantibody production and sustained immune dysregulation, driven by both germinal center and extrafollicular pathways.
3. Therapeutic Implications:
   • The presence of TLS suggests that B-cell depleting therapies (e.g., Rituximab) are mechanistically sound, though response rates in this cohort were variable, possibly due to the heterogeneity of the phenotype (e.g., IBM overlap).
   • The identification of TLS in patients with negative standard CD20 staining suggests that Cyc-IF could be a superior diagnostic tool for identifying patients who might benefit from targeted B-cell therapies.
4. Future Directions: The study highlights the need for prospective trials to determine if early B-cell targeting prevents the formation of TLS and improves long-term outcomes, particularly in patients with overlapping connective tissue diseases.

In summary, the paper establishes that prominent B cell aggregates in AIM are organized Tertiary Lymphoid Structures with distinct cellular architectures, redefining the pathophysiology of a subset of myositis patients and offering new targets for precision medicine.